Tnya vs tsha which stock to buy
11/14/2024 11:53am
**Tenaya Therapeutics (TNYA) appears to be the stronger investment option compared to Taysha Gene Therapies (TSHA) based on the following analysis**:
1. **Financial Ratios**: Tenaya Therapeutics has a higher Price-to-Earnings (P/E) ratio of 17.33 compared to Taysha Gene Therapies' P/E ratio of 6.2. A higher P/E ratio can indicate that investors are willing to pay more for a stock, which may suggest growth prospects.
2. **Price Target and Consensus Rating**: Tenaya Therapeutics has a higher average price target of $17.33, with a consensus rating of "Strong Buy". In contrast, Taysha Gene Therapies has a lower average price target of $6.2, also rated as "Strong Buy". The higher price target and consensus for TNYA could indicate greater confidence in its future performance.
3. **Recent Performance**: Tenaya Therapeutics saw a 20.39% increase in its stock price to $3.01, which is a positive sign. Taysha Gene Therapies rose by 27.56% to $2.08, showing significant gains but starting from a lower base.
4. **Fund Flow**: Tenaya Therapeutics had a net fund outflow of $254,857.52, which is less than Taysha Gene Therapies' outflow of $1.25 million. This could suggest less intense selling pressure on TNYA.
5. **Earnings Estimates**: Earnings estimates for Tenaya Therapeutics have been revised upwards, with the latest estimate showing a fiscal year 2024 earnings per share (EPS) of ($1.35), compared to the previous estimate of ($1.46). This indicates potential improvement in financial performance.
6. **Analyst Ratings**: Several analysts have given TNYA a "Buy" rating, with price targets ranging from $16.00 to $18.00. The consensus price target of $14.75 indicates potential upside from the current price.
7. **Market Sentiment**: Tenaya Therapeutics has received positive research reports, with analysts setting a higher price target and maintaining a "Buy" rating. This suggests a positive market sentiment towards the stock.
While both stocks have been rated as "Strong Buy," Tenaya Therapeutics appears to have a more favorable outlook based on the discussed factors. However, it's important to consider your investment goals, risk tolerance, and consult with a financial advisor before making any investment decisions.